Drugs in development for relapsing multiple sclerosis. - Wikidata - awgldk - TriplyDB

Drugs in development for relapsing multiple sclerosis.

Drugs in development for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q38101004

about

Fingolimod for relapsing-remitting multiple sclerosis Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Myelin recovery in multiple sclerosis: the challenge of remyelination Protocol to isolate a large amount of functional oligodendrocyte precursor cells from the cerebral cortex of adult mice and humans.Apigenin, a Natural Flavonoid, Attenuates EAE Severity Through the Modulation of Dendritic Cell and Other Immune Cell Functions.Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells The therapeutic potential of interleukin-10 in neuroimmune diseases.Alemtuzumab in the treatment of multiple sclerosis.Teriflunomide and its mechanism of action in multiple sclerosis.Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs.Review of laquinimod and its therapeutic potential in multiple sclerosis.Current evaluation of alemtuzumab in multiple sclerosis.Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.A basic overview of multiple sclerosis immunopathology.The future of multiple sclerosis treatments.Myeloid cells - targets of medication in multiple sclerosis.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades?Daclizumab: A Review in Relapsing Multiple Sclerosis.Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.Fingolimod (Gilenya® ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.RhoA Drives T-Cell Activation and Encephalitogenic Potential in an Animal Model of Multiple Sclerosis.Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.

P2860

Q24185882-F1D3AF4D-F48A-4262-B4B1-752520BD9866 Q24200823-FF86B382-37F0-4BED-B3B7-6A82DFC39695 Q26748229-7B475886-C10C-4B01-A77F-CFA23AD2E6D9 Q28081636-36AE1DFE-E8E3-4B36-BC1E-EDA485550665 Q30659100-CA6E4927-47A2-4C3F-8A2A-2A17A12F6E19 Q30808014-5C55EF5F-BD8E-487B-ABE9-C2492BA87918 Q30838717-2EBD08CE-2E2A-4913-A6CD-29011D982353 Q33772195-6AFD3D08-B286-4FB4-B2F9-791319643E0B Q35058625-76351386-4740-47ED-B5E7-1D8F550A4A8F Q36872742-BE5D7900-3BBC-4CD8-BD9A-EF536EF779E7 Q37071461-C2AF988D-1420-4576-85D9-4FEBD210045B Q37485007-3ABB5BC8-24D1-4FC4-B4B3-8BDF94891800 Q37649028-A87ED7E6-3215-4589-8154-A2B47A84EF74 Q37730005-B2357480-B3D8-4842-BA92-F47BDC99C914 Q38124678-5F2D2166-5BE8-4DE8-95A0-4231EAFD4ED9 Q38161575-83E909C3-8B97-4C9C-806E-61FBCE8E6187 Q38167350-A8D0424C-89ED-45EF-9C9C-34F189319F58 Q38192006-0044B0F4-6A2B-4A7B-8C35-39B2B5443D46 Q38558344-775F3DCF-3BA3-4CF1-842C-279EECF88568 Q38587668-0CC043F2-DC5E-46F5-84F1-8381B8AFC96D Q38808485-FB402FE7-25C6-43B1-8CD2-59134F06CD96 Q38924828-A16EBAEC-8876-464D-B2A3-602DB10CE8EA Q39049796-E49C71F7-F8E8-4A1A-A840-7D6076CCED80 Q39069841-FCBE310B-EF3F-4011-9B42-9C27A3EDB143 Q39140303-C04E5009-90B8-4D0D-8952-C48511A20D22 Q43905322-190F51C2-9068-49E8-A52C-2FCF26DF1108 Q46480858-9C723F51-DFF4-4577-A60A-DBB1EF1552ED Q47409416-7F779F38-4F10-43B7-9D16-672B6E12ACA4 Q55082007-37B8DEE6-1967-4A5E-AE05-2D9B729EAFC7 Q55445399-79DF5F4A-A67E-432C-85FA-F81412C99FDE

P2860

Drugs in development for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q38101004

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Drugs in development for relapsing multiple sclerosis.

@en

type

label

Drugs in development for relapsing multiple sclerosis.

@en

prefLabel

Drugs in development for relapsing multiple sclerosis.

@en

P1433

Q38101004-57EE4C39-4E22-44B9-A8A1-6D99EF2548E2

P1476

Q38101004-0EE33434-DDBD-47E9-8619-95C47975E7B3

P2093

Q38101004-00C5BEC5-8EE7-472F-B6FD-D3B333839B04

Q38101004-15BEC876-75FC-4885-AC59-702EB56661D4

P2860

Q38101004-029C2DFB-CD70-451C-96B0-E5491B9C2B4D

Q38101004-02B72C41-BF22-4472-9606-FD444D7FFA35

Q38101004-05B8EF98-6F3B-4A95-BBB9-F129E7877A8A

Q38101004-06CE0134-BE1F-4EC5-8268-90AAEB42E541

Q38101004-07E9E54D-784F-4B3C-8CE0-B05CB8AB7994

Q38101004-0C162C52-5AAC-464F-A9D2-114FD857E1FC

Q38101004-0C359FFD-41D3-4DAC-87FA-AF3EE35F8BDE

Q38101004-0D3C938E-1A96-4986-8D51-1E6B63665CCB

Q38101004-0EBC5CCA-09E5-4082-B497-5A75F6C8F7BD

Q38101004-0F103F66-6BFC-4985-B683-3E2D9D820E56

P2888

Q38101004-90965116-95F4-43C9-95D7-3CDDC3B395A9

P304

Q38101004-A6662653-5E96-424C-BFC4-B8100CF44BA9

P31

Q38101004-FBF83424-326F-469F-8BFE-698741F0E7E6

P356

Q38101004-6D188C63-E251-4C7C-AD0B-6B213B71E1AE

P433

Q38101004-E7B5C1EF-97BD-4035-92EF-B76E5F5520CD

P478

Q38101004-C869DA8B-8B39-4C07-A213-98E729F1A30F

P50

Q38101004-6110B65F-708E-48A0-ABD3-CDB5E9A54AA9

P577

Q38101004-5DE0CAC0-3CBE-4396-AC80-86821F94DB42

P6179

Q38101004-172240AD-D62A-4310-B383-8765090BC740

P698

Q38101004-17CA8919-ED6F-4F44-8E87-B38D8822EA58

P921

Q38101004-67E53FAE-E539-42AB-96E3-EF262813E363

P356

S40265-013-0030-6

P1433

P1476

Drugs in development for relapsing multiple sclerosis.

@en

P2093

Rehiana Ali

http://www.w3.org/2001/XMLSchema#string

Richard St John Nicholas

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Continuous cultures of fused cells secreting antibody of predefined specificity

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

Mechanism of action for leflunomide in rheumatoid arthritis

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ocrelizumab: a step forward in the evolution of B-cell therapy

Paul Ehrlich's magic bullets

P2888

s40265-013-0030-6

P304

625-650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0030-6

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011109109

http://www.w3.org/2001/XMLSchema#string

P698

23609782

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis